Biomea Fusion, INC 8-K filings

Biomea Fusion, Inc. announced the results of its Annual Meeting of Stockholders, including the election of two directors and the ratification of its independent auditor.

Biomea Fusion announced its first quarter 2026 financial results, highlighting progress in its icovamenib and BMF-650 clinical trials for diabetes and obesity, with a projected cash runway into Q1 2027.

Biomea Fusion announced positive 52-week topline results from its Phase 2 COVALENT-112 study of icovamenib in Type 1 Diabetes patients, showing significant C-peptide increase and durability.

Biomea Fusion, Inc. announced its full year 2025 financial results, highlighting significant progress in its diabetes and obesity clinical programs and a reduced net loss.

Biomea Fusion, Inc. updated its corporate presentation, highlighting progress in its diabetes and obesity programs, icovamenib and BMF-650, with key clinical data readouts anticipated in 2026 and funding secured into Q1 2027.

Biomea Fusion presented positive 52-week data for its diabetes drug Icovamenib and preclinical results for its obesity candidate BMF-650 at the J.P. Morgan Healthcare Conference.

Biomea Fusion reported Q3 2025 financial results, highlighting positive Phase II icovamenib data, the initiation of a Phase I BMF-650 study, and an extended cash runway into Q1 2027.

Biomea Fusion, a clinical-stage diabetes and obesity company, announced the pricing of an underwritten public offering expected to generate approximately $25.0 million in gross proceeds.

Biomea Fusion, Inc. announced positive 52-week results from its Phase II COVALENT-111 study of icovamenib in Type 2 diabetes, showing durable HbA1c reductions in key patient subgroups.

Biomea Fusion reported its second quarter 2025 financial results, highlighting positive clinical data for icovamenib and BMF-650, a successful $42.8 million public offering, and significant cost reductions.

Biomea Fusion, Inc. announced the appointment of Julianne Averill as a Class III Director and Audit Committee member, following the resignation of Bihua Chen from the Board.

Biomea Fusion, Inc. has successfully closed an underwritten public offering, raising approximately $37.1 million in net proceeds through the sale of common stock, pre-funded warrants, and accompanying common stock warrants.

Clinical-stage biotechnology firm Biomea Fusion, Inc. announced the pricing of an underwritten public offering of common stock and warrants, raising an estimated $37.1 million in net proceeds, with units offered at a substantial discount to the recent trading price.

Biomea Fusion, Inc. announced compelling preclinical results for its oral GLP-1 RA candidate BMF-650 in obese non-human primates and durable HbA1c reductions with beta-cell restoration in Type 2 Diabetes patients treated with Icovamenib.

Biomea Fusion, Inc. announced the results of its Annual Meeting, where shareholders re-elected three Class I directors and ratified Deloitte & Touche LLP as its independent auditor, but rejected a proposal to limit officer liability, leading to an adjournment to solicit further proxies.

Biomea Fusion is focusing on core programs and cutting costs to extend its cash runway into the fourth quarter of 2025.

Biomea Fusion announced its Q4 and full year 2024 financial results, the appointment of Mick Hitchcock as Interim CEO, and plans to advance icovamenib into late-stage clinical development.

Biomea Fusion appoints Mick Hitchcock as interim CEO, replacing Thomas Butler, to drive the company's diabetes therapy development.

Franco Valle resigned as Chief Financial Officer of Biomea Fusion, Inc., effective March 7, 2025, with no disagreements cited as the reason for his departure.

Biomea Fusion announces a strategic shift to focus on diabetes and obesity medicines, with icovamenib showing promising results in insulin-deficient patients and in combination with GLP-1 therapies.

Biomea Fusion's icovamenib demonstrated a statistically significant reduction in HbA1c levels in type 2 diabetes patients, particularly those with insulin deficiency, in a Phase II trial.

Biomea Fusion announced preclinical data showing their drug icovamenib enhances GLP-1 based therapies and introduced a new oral GLP-1 receptor agonist, BMF-650.

Biomea Fusion reported its third quarter 2024 financial results, highlighted by the lifting of the clinical hold on its diabetes trials and the advancement of a new GLP-1 receptor agonist.

The FDA has lifted the clinical hold on Biomea Fusion's BMF-219 trials for type 2 and type 1 diabetes, allowing the studies to resume.

Biomea Fusion reported its second quarter 2024 financial results, highlighted by progress in its clinical programs and a clinical hold on its diabetes drug.

Biomea Fusion held its annual stockholder meeting on June 12, 2024, where directors were elected and the appointment of an independent accounting firm was ratified.

The FDA has placed a full clinical hold on Biomea Fusion's BMF-219 diabetes drug trials due to observed hepatotoxicity.

Biomea Fusion announced positive clinical data for their diabetes drug BMF-219 and reported their first quarter 2024 financial results, including a cash position of $145.3 million.

Biomea Fusion reports initial positive results from the first two type 1 diabetes patients treated with BMF-219, showing improved beta-cell function.

Biomea Fusion announced positive clinical data for its diabetes programs and provided a financial update for the fourth quarter and full year 2023, highlighting progress in both metabolic disease and oncology pipelines.